Review: Sirtuin modulators and cognitive ageing in Alzheimer's disease
This review summarises how sirtuins, NAD⁺-dependent enzymes, are linked to ageing and Alzheimer's disease, and how diet, exercise and natural compounds that modulate them are discussed as a possible therapeutic avenue. [1]
Automatic summary · not editorially reviewed
The key findings
Sirtuins are described as NAD⁺-dependent class III histone deacetylases with key functions in biological processes involved in ageing. [1]
Downregulation of some specific sirtuins has been reported in ageing and in some neurological diseases such as Alzheimer's disease. [1]
Diet, exercise and various natural compounds are presented as a potential new therapeutic avenue to modify Alzheimer's progression and delay some ageing effects. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Literature on sirtuins in ageing, cognitive function and Alzheimer's disease; no human participants described in the abstract.
- Summary based on
- Study abstract
- Original publication
- October 3, 2026
Sirtuins in ageing and Alzheimer's disease
The review describes sirtuins as NAD⁺-dependent class III histone deacetylases with key functions in many biological processes involved in ageing. It reports that downregulation of some specific sirtuins has been reported in ageing and in some neurological diseases such as Alzheimer's disease. These are reported associations from the reviewed literature, not established causes.
Supporting source [1]
Diet, exercise and compounds as sirtuin modulators
According to the abstract, sirtuin modulator factors such as diet, exercise and various natural compounds have recently emerged as a potential new avenue of therapy. The stated aims are to modify the progression of Alzheimer's disease and delay some ageing effects. The abstract presents this as a potential avenue, not as a demonstrated treatment benefit.
Supporting source [1]
Scope of this review on healthy cognitive ageing
The review synthesises recent advances in understanding the modulatory effects of sirtuins in the context of healthy ageing, with particular focus on cognitive function and implications for Alzheimer's disease. Only the abstract was reviewed; the full text was not reviewed. The abstract reports no study design, sample, follow-up or outcome data, so no effect sizes or certainty of benefit can be stated.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The abstract reports no study design, sample size, follow-up, outcome data or effect estimates, and the therapeutic potential is described as emerging, not demonstrated.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
McDermott C, Cole MH, Pearson M, Winberg P, Fernandez F. · europepmc.org · October 3, 2026